Francis C. Lynn on tracking insulin- and glucagon-expressing cells, David C. Wraith & Michael J. Price on antigen-specific immunotherapy for T1D, and Sweet Talk with Bret H. Goodpaster

Welcome to the February 2025 episode of DiabetesBio—the American Diabetes Association’s podcast for its flagship research publication, Diabetes. In this episode of DiabetesBio, Drs. Kirk Habegger, Darleen Sandoval, and Kevin Williams discuss the latest and greatest content in the February 2025 issue of Diabetes.

3:55 In the first interview segment, our hosts our joined by Francis C. Lynn, BSc PhD, Associate Professor in the Department of Surgery and School of Biomedical Engineering at the University of British Columbia in Vancouver. He is the corresponding author of the article “Tracking Insulin- and Glucagon-Expressing Cells In Vitro and In Vivo Using a Double-Reporter Human Embryonic Stem Cell Line.” The article is available for free at doi.org/10.2337/db24-0756.

18:25 Darleen, Kevin, and Kirk speak with David C. Wraith, PhD, Emeritus Professor of Immunology, and Michael J. Price, PhD, a research fellow, both at the Institute of Immunology and Immunotherapy at the University of Birmingham in the UK. They discuss their article, “Pre-clinical development of a tolerogenic peptide from glutamate decarboxylase as a candidate for antigen-specific immunotherapy in type 1 diabetes,” available at doi.org/10.2337/db23-0996.

35:50 In the latest edition of “Sweet Talk,” our hosts welcome Bret H. Goodpaster, PhD, Scientific Director and Senior Investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, FL, and Professor of Medicine at Johns Hopkins University.

To learn more about Diabetes and DiabetesBio, please visit diabetesjournals.org/diabetes. Thank you for listening, and don’t forget to smash that “follow” button!